CytoMed Therapeutics LtdGDTC
Price (close)
$0.91
Market cap
$10.8M
P/E
—
Revenue (FY)
$324,387
Net income
-$4.0M
Dividend yield
—
1-year total return
-53.8%
Net margin
-1227.1%
Revenue growth
366.7%
Debt / equity
0.06x
What CytoMed Therapeutics Ltd does.
are a clinical stage biopharmaceutical company focused on harnessing our proprietary technologies into creating novel cell-based immunotherapies
for treatment of human cancers and degenerative diseases. The development of our novel technologies has been inspired by the clinical
success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $69,501 | $324,387 |
| Net income | -$1.9M | -$2.1M | -$3.1M | -$4.1M | -$2.5M | -$4.0M |
| Free cash flow | -$1.1M | -$2.3M | -$1.9M | -$3.6M | -$4.1M | -$4.3M |
More on GDTC.
- CytoMed Therapeutics Ltd summary
- CytoMed Therapeutics Ltd financial statements
- CytoMed Therapeutics Ltd key metrics
- CytoMed Therapeutics Ltd health scores and style box
- CytoMed Therapeutics Ltd earnings
- CytoMed Therapeutics Ltd dividends
- CytoMed Therapeutics Ltd valuation
- CytoMed Therapeutics Ltd ownership and insiders
- CytoMed Therapeutics Ltd peers
Figures from CytoMed Therapeutics Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.